Both the Pharmaceutical Research and Manufacturers of America and the nonprofit group have gone to great lengths to show that drugmakers are not driving what they describe as a “grass-roots” effort to fight imports.
Nine U.S. senators are pushing the U.S. Attorney General to reveal what he knows about a reported investigation into Tom Price’s stock trades that a top federal prosecutor might have begun before being fired by the Trump administration.
At least 83 percent of the United States’ largest patient advocacy groups take contributions from the drug industry, and not all of them are transparent about it.